Department of Oncology/Haematology, Niguarda Ca'Granda Hospital, Piazza Ospedale Maggiore 3, 20162 Milano, Italy.
Expert Rev Hematol. 2012 Feb;5(1):43-6. doi: 10.1586/ehm.11.75.
First-line chemoimmunotherapy approaches offer prolonged disease-free survival in patients with chronic lymphocytic leukemia (CLL). Despite the improved results with purine analogs ± cyclophosphamide and rituximab (FCR) the disease remains incurable, and patients with CLL are destined to relapse after primary treatment. The prior therapy administered and the response, and duration of response to that therapy, are among the most important factors in determining the next therapy. Bendamustine, a bifunctional alkylating agent, combined with rituximab (BR) has been tested in patients with relapsed and/or refractory CLL in order to investigate the safety and efficacy of this combination. In conclusion, chemoimmunotherapy with BR showed interesting results, with the exception of patients carrying del(17p). Bendamustine appears to be a good choice for second-line therapy owing to its lack of significant cross-resistance with other alkylating agents or fludarabine.
一线化疗免疫治疗方法可为慢性淋巴细胞白血病 (CLL) 患者提供延长的无病生存期。尽管嘌呤类似物联合环磷酰胺和利妥昔单抗 (FCR) 的治疗结果有所改善，但该疾病仍无法治愈，并且 CLL 患者在初次治疗后注定会复发。先前接受的治疗以及对该治疗的反应和反应持续时间是决定下一步治疗的最重要因素之一。苯达莫司汀是一种双功能烷化剂，与利妥昔单抗 (BR) 联合用于复发和/或难治性 CLL 患者，以研究该联合用药的安全性和疗效。总之，BR 的化疗免疫治疗显示出了有趣的结果，但 17p 缺失的患者除外。由于与其他烷化剂或氟达拉滨无明显交叉耐药性，苯达莫司汀似乎是二线治疗的不错选择。
